Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers.
|Articles|April 21, 2015
Dr. Primo Lara Discusses Emerging Therapies in Kidney Cancer
Primo Neary Lara Jr., associate director of Translational Research at the UC Davis Comprehensive Cancer Center, discusses emerging therapies for patients with kidney cancer.
Advertisement
Primo Neary Lara Jr., associate director of Translational Research and co-leader of the Cancer Therapeutics Program at UC Davis Comprehensive Cancer Center, discusses emerging therapies for patients with kidney cancer.
Advertisement
Related to this article
Dr. Morana Vojnic answers common questions about brain cancer, including diagnosis, tumor types, treatment effects, recurrence and life after treatment begins.
Dr. Jacqueline Barrientos shares how a targeted therapy, a determined care team and a stranger’s generosity gave a 72-year-old man with hairy cell leukemia and kidney failure a second chance.
Dr. Robert Kreitman explains how CD22-targeted CAR T could help heavily pretreated patients.
An expert at ESMO 2026 explains how liquid biopsy and ESR1 testing can help guide treatment for people with HR-positive metastatic breast cancer.
Psychiatrist Dr. Yesne Alici of Memorial Sloan Kettering Cancer Center answers questions about family relationships during cancer, from asking for help to talking with children and friends.
After breast cancer at 30, Aisha shares her journey through motherhood, a double mastectomy, body image struggles and the challenges of survivorship.
Advertisement
Advertisement
Trending on CURE
1
Top 5 Takeaways From ESMO 2026 That Patients Should Know
2
4 Long-Term Survival Results From ESMO 2026 Patients Should Know
3
Life After a Prostate Cancer Diagnosis: Why It’s a Pivot, Not an Ending
4
How to Appeal an Insurance Denial for Cancer Treatment
5